Art

J-GLOBAL ID：201702238244608496   Reference number：17A0226448

婦人科腫瘍 婦人科がん領域における化学療法の現状と将来像 I.卵巣癌

Author (2)： YOKOYAMA TAKAAKI (日本医大 武蔵小杉病院 腫瘍内科) ,  KATSUMATA NORIYUKI (日本医大 武蔵小杉病院 腫瘍内科)
Material： 癌と化学療法  (Japanese Journal of Cancer and Chemotherapy)
Volume： 44  Issue： 2  Page： 123-125  Publication year： Feb. 15, 2017 
JST Material Number： Z0938A  ISSN： 0385-0684  Document type： Article
Article type： 文献レビュー  Country of issue： Japan (JPN)  Language： JAPANESE (JA)

Thesaurus term： human(primates) ,...
Semi thesaurus term： *PARP inhibitor ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0226448&from=J-GLOBAL&jstjournalNo=Z0938A") }}

JST classification (2)： Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Tumors(=neoplasms)of female genitalia and fetus  (GS04000K)

Substance index (4)： Niraparib ,  Rucaparib ,  Veliparib ,  Olaparib

Reference (10)：

• Ledermann J, Harter P, Gourley C, et al: Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366 (15): 1382-1392, 2012.
• Ledermann J, Harter P, Gourley C, et al: Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15 (8): 852-861, 2014.
• Oza AM, Cibula D, Benzaquen AO, et al: Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 16 (1): 87-91, 2015.
• Coleman RL, Sill MW, Bell-McGuinn K, et al: A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation-an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 137 (3): 386-391, 2015.
• Mirza MR, Monk BJ, Herrstedt J, et al: Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375 (22): 2154-2164, 2016.

Terms in the title (6)： 婦人科腫瘍 ,  婦人科がん ,  化学療法 ,  現状 ,  将来 ,  卵巣癌